Drug Approval | March 06, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The company will engage with the agency to resolve the import alert at the earliest.
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Subscribe To Our Newsletter & Stay Updated
